2026 Symposium Archive (Statesboro)
LAT1-Acridine Drug Targeting In Pancreatic Cancer Cells
Faculty Mentor
Rebecca Kocerha
Location
Russell Union Ballroom
Type of Research
On-going
Session Format
Poster Presentation
College
College of Science & Mathematics
Department
Department of Biology
Abstract
LAT1-Acridine Drug Targeting in Pancreatic Cancer Cells
Pancreatic cancer cells have high metabolic demands and commonly overexpress the L-type Amino Acid Transporter 1 (LAT1), which increases nutrient uptake to support rapid growth. Because LAT1 expression is increased across cancer types, it represents a potential target for selective drug delivery. In this study, acridine, a compound with well established cytotoxic and fluorescent properties, will be modified into a LAT1-transported drug. A pancreatic cancer cell line that represents an aggressive and metastatic form of the primary tumor, will be treated with conjugates and the impact on cell viability will be quantified with a commercially available colorimetric assay . Drug uptake and intracellular localization will be evaluated with confocal microscopy imaging. The LAT1-drugs are expected to demonstrate increased uptake and enhanced cytotoxicity in pancreatic cancer cells compared to cells treated with an inactive derivative of the drug as well in cells of a non-cancerous origin , supporting the use of LAT1 as a strategy for selective therapeutic delivery.
Program Description
.
Start Date
4-23-2026 2:00 PM
End Date
4-23-2026 4:00 PM
Copyright
This work is archived and distributed under the repository's Standard Copyright and Reuse License (opens in new tab). End users may copy, store, and distribute this work without restriction. For all other uses, permission must be obtained from the copyright owners or their authorized agents.
Recommended Citation
Harris, Adelyn I., "LAT1-Acridine Drug Targeting In Pancreatic Cancer Cells" (2026). GS4 Student Scholars Symposium. 157.
https://digitalcommons.georgiasouthern.edu/research_symposium/2026/2026/157
LAT1-Acridine Drug Targeting In Pancreatic Cancer Cells
Russell Union Ballroom
LAT1-Acridine Drug Targeting in Pancreatic Cancer Cells
Pancreatic cancer cells have high metabolic demands and commonly overexpress the L-type Amino Acid Transporter 1 (LAT1), which increases nutrient uptake to support rapid growth. Because LAT1 expression is increased across cancer types, it represents a potential target for selective drug delivery. In this study, acridine, a compound with well established cytotoxic and fluorescent properties, will be modified into a LAT1-transported drug. A pancreatic cancer cell line that represents an aggressive and metastatic form of the primary tumor, will be treated with conjugates and the impact on cell viability will be quantified with a commercially available colorimetric assay . Drug uptake and intracellular localization will be evaluated with confocal microscopy imaging. The LAT1-drugs are expected to demonstrate increased uptake and enhanced cytotoxicity in pancreatic cancer cells compared to cells treated with an inactive derivative of the drug as well in cells of a non-cancerous origin , supporting the use of LAT1 as a strategy for selective therapeutic delivery.
